-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18

Benzinga·12/19/2025 14:54:12
语音播报
Stifel analyst Annabel Samimy maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $15 to $18.